Rituxan (rituximab) - Roche
Suprabasal Blistering as a Diagnostic Pitfall in Bullous Pemphigoid: Histopathologic-Immunofluorescence Discordance Complicated by Sepsis. (PubMed, Cureus) - Oct 4, 2026 - "The patient also developed progressive multifactorial anemia, sepsis-associated coagulopathy, and upper gastrointestinal bleeding. Following multidisciplinary management, she achieved near-complete resolution of skin lesions and clinical recovery, and was discharged with plans for rituximab as definitive steroid-sparing therapy.  This case highlights two critical lessons: first, a suprabasal blister on histopathology does not exclude bullous pemphigoid, as re-epithelialization can alter the apparent cleavage plane, making DIF indispensable for an accurate diagnosis; second, severe bullous pemphigoid requiring intensive immunosuppression carries a substantial risk of sequential nosocomial infections warranting close microbiological surveillance, early source control, and timely modulation of immunosuppressive regimens." 
Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Diabetic Neuropathy • Gastroenterology • Hematological Disorders • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Pain • Pemphigus Vulgaris • Pneumonia • Respiratory Diseases • Septic Shock • Type 2 Diabetes Mellitus
http://www.ncbi.nlm.nih.gov/pubmed/42827875
 
Adriana V Saenz; Anna K Bustillos; Marisol Cazares; Mauro A Cardenas; Sarahi G Romero; Sofia de La O
 
Oct 4, 2026
 
Prev Next